Goldman Sachs Group Inc. Sells 36,174 Shares of Semler Scientific Inc. $SMLR

Key Points

• Goldman Sachs Group Inc. reduced its stake in Smeler Scientific Inc. by 32% in the first quarter, owning approximately 0.69% of the company valued at $2.78 million after selling 36,174 shares.
• Semler reported $5.04 EPS for the last quarter, significantly exceeding the consensus estimate of ($0.27), with a return on equity of 43.84% and a net margin of 86.20%.
• Research analysts maintain a consensus rating of "Buy" for Semler Scientific, with an average price target of $78.00, despite recent adjustments to price targets by firms like Cantor Fitzgerald and Maxim Group.

Goldman Sachs Group Inc. trimmed its position in shares of Semler Scientific Inc. (NASDAQ:SMLR - Free Report) by 32.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 76,799 shares of the company's stock after selling 36,174 shares during the period. Goldman Sachs Group Inc. owned 0.69% of Semler Scientific worth $2,780,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SMLR. BNP Paribas Financial Markets purchased a new position in Semler Scientific during the 4th quarter worth approximately $30,000. Cetera Investment Advisers purchased a new position in Semler Scientific during the 4th quarter worth approximately $965,000. D. E. Shaw & Co. Inc. purchased a new position in Semler Scientific during the 4th quarter worth approximately $439,000. Nuveen Asset Management LLC grew its position in Semler Scientific by 396.9% during the 4th quarter. Nuveen Asset Management LLC now owns 124,548 shares of the company's stock worth $6,726,000 after purchasing an additional 99,482 shares in the last quarter. Finally, Pinnacle Wealth Management LLC purchased a new position in Semler Scientific during the 4th quarter worth approximately $2,279,000. 49.37% of the stock is currently owned by hedge funds and other institutional investors.

Semler Scientific Stock Performance

Semler Scientific stock traded up $0.76 on Tuesday, reaching $32.82. 1,346,668 shares of the stock were exchanged, compared to its average volume of 716,474. The stock has a market cap of $486.09 million, a PE ratio of 13.52 and a beta of 1.39. The company has a current ratio of 0.60, a quick ratio of 0.58 and a debt-to-equity ratio of 0.25. Semler Scientific Inc. has a twelve month low of $22.01 and a twelve month high of $81.56. The firm has a fifty day moving average price of $33.48 and a two-hundred day moving average price of $35.41.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $5.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $5.31. The firm had revenue of $8.22 million during the quarter, compared to analyst estimates of $8.10 million. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald decreased their target price on shares of Semler Scientific from $61.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, August 6th. Benchmark decreased their target price on shares of Semler Scientific from $101.00 to $86.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Maxim Group decreased their target price on shares of Semler Scientific from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $74.25.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.